Areas of research and development in the Therapeutics Market

  • Creation of vaccines
  • Sterilization of biologics/vaccines
  • Extraction of ethylene oxide from APIs
  • Endospore impregnation with therapeutics for solid tumor targeting

NovaSterilis has a long history of developing terminal sterilization solutions for small molecule therapeutics (“APIs”). Multiple API-specific NovaSterilis sterilization processes have been successfully demonstrated; no impact to physical properties or biological function of the APIs.

Beyond terminal sterilization, NovaSterilis has developed a process to extract residual ethylene oxide trapped within finished APIs, which were sterilized utilizing ethylene oxide. This process allows currently approved therapeutics to be sold in markets where regulations require residual ethylene oxide to be below a threshold they have not been historically able to achieve with conventional outgassing techniques.

Large molecule therapeutics (biologics and vaccines) are a current focus of NovaSterilis’ development efforts. NovaSterilis has developed multiple processes for not only the sterilization of large molecule therapeutics but it has also developed processes for the creation of vaccines. NovaSterilis is looking to grow the number of active partnerships in this market.

In an emerging area of research, NovaSterilis has merged small molecule therapeutics with sterilized endospore delivery vehicles for the targeting of anaerobic solid tumors. A research partner is being sought for the next stage of research activities.